Hematopoietic macrochimerism, established by bone marrow transplantation, can be used as an approach for treating autoimmune disease and inducing transplant tolerance. In this study, we investigated whether a stable, high level of fully MHC-mismatched hematopoietic macrochimerism can be induced by using irradiation-free protocols, and whether rapamycin and 
One of the major goals in the fields of transplantation and autoimmune disease is to reprogram the host immune system to induce or restore long-term tolerance after shortterm immunosuppressive therapy. In small animal models, irradiation-induced myeloablation or myelosuppression, followed by donor hematopoietic cell reconstitution has so far been the most successful approach for inducing hematopoietic macrochimerism and tolerance. However, clinical application of bone marrow transplantation for nonmalignant diseases has not been widely accepted because of the toxicity of irradiation conditioning therapy and related complications.
Full hematopoietic chimerism and mixed hematopoietic chimerism in preconditioned hosts can be induced by bone marrow transplantation. Low levels of stable donor chimerism may be adequate to induce transplant tolerance and control autoreactivity in the setting of organ or tissue transplants and autoimmune disease. Initial studies by Ildstad and Sachs 1 showed that mixed hematopoietic chimerism could be induced by using lethal irradiation and reconstitution with a mixture of T cell-depleted donor and host bone marrow. Cobbold et al 2 further demonstrated that allogeneic bone marrow engraftment and specific tolerance could be achieved by sublethal doses of total body irradiation and deleting anti-CD4 and anti-CD8 monoclonal antibodies. Subsequently, hematopoietic macrochimerism as an approach for inducting transplantation tolerance in small animal models has been extensively investigated, using irradiation as a conditioning therapy. 3, 4 Recent studies have indicated that hematopoietic macrochimerism can be induced by either costimulatory blockade and high-dose bone marrow infusion 5 or by repeated bone marrow infusion. 6 Hale et al 7 also reported that stable hematopoietic macrochimerism can be established by a high dose of bone marrow and anti-lymphocyte serum (ALS) plus rapamycin treatment. However, these protocols may be difficult to apply clinically, because of the total number of bone marrow cells required for transplantation. With modest doses of bone marrow, it seems that myelosuppressive conditioning therapy is essential for bone marrow engraftment even with a syngeneic bone marrow transplantation. 8 Tomita et al 9 recently showed that hematopoietic macrochimerism can be induced in fully MHC-mismatched mice after donor spleen cell pretreatment followed by myelosuppressive busulfan and cyclophosphamide.
In this study, we investigated whether mixed hematopoietic chimerism can be induced under our nonirradiative conditioning therapy and the effect of post-transplant rapamycin and costimulatory blockade treatment in promoting bone marrow engraftment. Our approach included a donorspecific blood transfusion (DST) 7 days pretransplantation. Rabbit anti-mouse lymphocyte serum (ALS) was given 1 day before and 2 days after DST to eliminate alloactivated host T cells. Busulfan and cyclophosphamide was used to suppress the host bone marrow lymphohematopoietic cells 4 and 5 days after DST. Costimulatory blockade (anti-CD154 monoclonal antibody (mAb) and CTLA4Ig) and rapamycin were used to enhance induction of mixed chimerism and to prevent graft-versus-host disease (GVHD) after bone marrow transplantation.
Materials and methods

Animals
Male Balb/c mice and male C57BL/6 mice, all 7 to 11 weeks old, were purchased from Taconic Farms (Germantown, NY, USA). All mice were maintained under pathogenfree conditions at our facility. Balb/c mice served as bone marrow donors and C57BL/6 mice served as recipients. All experiments related to these mice were performed according to the protocols reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota.
Bone marrow transplantation
The femoral and tibial bones from donor Balb/c mice were removed and the bone marrow was flushed out with PBS using a 10 ml syringe with a 26-gauge needle. Cell suspensions were washed twice with RPMI 1640 medium. Viable cells were counted and were adjusted to 8 ϫ 10 7 cells/ml. Half the bone marrow cells (4 ϫ 10 7 ) was injected into each mouse through the tail vein.
Treatment
For DST, Balb/c donor blood (0.25 ml) was infused into fully mismatched C57BL/6 mice through the tail vein. ALS (Accurate Chemical & Scientific, Westbury, NY, USA) was given to these mice at at a dose of 0.3 ml 1 day before and 2 days after DST. Busulfex (busulfan; Orphan Medical, Minnetonka, MN, USA) at 20 mg/kg and cytoxan (cyclophosphamide; Bristol-Myers Squibb Co, Princeton, NJ, USA) at 100 mg/kg was administered intraperitoneally (i.p.) 4 and 5 days post DST. Anti-CD154 mAb (MR1; Bio Express, West Lebanon, NH, USA) at 0.5 mg was given i.p. on day 0 and day 2 post transplant. CTLA4Ig, which was obtained from a Chinese hamster ovary cell line that secreted CTLA4Ig fusion protein as previously published, 10 was given at 0.5 mg i.p. on day 2 post transplant. Rapamune (rapamycin; Wyeth Laboratories, Philadelphia, PA, USA) was given at 1 mg/kg by gavage from day Ϫ1 to day 2 post transplant, then once every 2 days until day 14 post transplant. 
Flow cytometric analysis
Enzyme-linked immunospot (ELISPOT) assay
ELISPOT assay for interferon (IFN)-␥ secreting cells was performed as previously described by Heeger's group. 11 Briefly, ELISPOT plates (Cellular Technology, Columbus, OH, USA) were coated overnight with anti-IFN-␥ mAb in sterile PBS, and blocked for 1 h with sterile PBS-1% bovine serum albumin. After washing three times with PBS, 0.5 ϫ 10 6 splenocytes from chimeric or nonchimeric mice were cultured in each well with 0.5 ϫ 10 6 mitomycin Ctreated donor spleen cells in HL-1 medium (BioWhittaker, Walkersville, MD, USA) at 37°C for 24 h. Cells were removed from the culture wells and the wells were washed with PBS-0.025% Tween, then assayed for cytokine capture by incubating with biotin-conjugated anti-IFN-␥ antibodies. After adding alkaline phosphatase and substrate, spots produced by cytokine producing splenocytes were seen. The plates were enumerated using a dissection microscope.
Mixed lymphocyte reactions (MLR)
Splenocytes were cultured in triplicate wells containing 5 ϫ 10 5 responder cells with 5 ϫ 10 5 irradiated (3000 cGy) stimulator cells in RPMI 1640 medium supplemented with 5% FBS, 0.53 mg/ml l-glutamine, 0.11 mg/ml sodium pyruvate, 100 U/ml penicillin, 100 g/ml streptomycin, 25 mm Hepes, and 55 mm 2-mercaptoethanol. After culture at 37ºC for 3 days, 3 H thymidine was added. Cells were harvested 18 h later and thymidine incorporation was measured.
Statistics
The significance of differences between the control and the treatment groups was determined by Student's t-test. A P value Ͻ0.05 was considered statistically significant.
Results
Fully MHC-mismatched allogeneic hematopoietic macrochimerism was induced by our protocol
We first determined whether hematopoietic macrochimerism was induced in our irradiation-free protocol. Then we further determined the effect of DST in our protocol. Following ALS, busulfan and cyclophosphamide as conditioning therapy, bone marrow transplantation, and rapamycin, anti-CD154 mAb and CTLA4Ig as post-transplant treatment with or without DST, peripheral blood samples were collected at different time points. To analyze the donorderived cells in the C56BL/6 mice, we gated the lymphocytes, granulocytes and monocytes, respectively. A stable and high level of hematopoietic macrochimerism was established in all recipient mice with or without DST. As shown in Figure 1 , donor-specific H-2D d -positive lymphocytes were detected 8 weeks post transplant. A similar level of donor granulocytes and monocytes was also detected (data not shown). Interestingly, the level of donor chimerism gradually increased. As shown in Figure 2 , the average percentage of donor-derived cells was 55.7 Ϯ 18.6% at 2 weeks post transplant; 74.8 Ϯ 4.8% at 8 weeks; and 89.0% Ϯ 3.5% at 20 weeks (n ϭ 5). The level of hematopoietic macrochimerism was significantly reduced without DST, although hematopoietic macrochimerism could be detected in all five recipients and level of donor-derived cells gradually increased. Without DST, the average of donor-derived cells was 25.6 Ϯ 16.5% at 2 weeks; 34.3 Ϯ 7.4% at 8 weeks; and 51.8 Ϯ 8.6% at 20 weeks (P Ͻ 0.01 vs DST-treated group). Thus, DST enhanced bone marrow engraftment.
All mice were healthy, with no signs of GVHD-like syndrome (eg diarrhea, hunched posture, mincing gait, anemia (whitish eyeballs) and dermatitis). Body weight did not significantly change in either group, although it did slightly increase in both groups at 20 weeks ( Figure 3 ). As shown in Table 1 , of six recipients that received busulfan and cyclophosphamide but not ALS, only one showed chimerism 8 weeks post transplant. If ALS but not busulfan and cyclophosphamide were given, donor H-2D d -positive cells could not be detected in any of the six recipients. Thus, busulfan and cyclophosphamide conditioning therapy is required to induce hematopoietic macrochimerism.
Rapamycin and T cell costimulatory blockade as posttransplant treatment promoted bone marrow engraftment
The effect of different post-transplant treatments on promoting bone marrow engraftment in our protocol was determined. Without any post-transplant treatment, donor chimerism was detected in only one of six recipients at 8 weeks post transplant ( (Table 1) . However, no recipient mice died at 8 weeks even if bone marrow engraftment failed. In the 15 mice that received busulfan and cyclophosphamide, no donor chimerism was detected at 2, 4, 6 or 8 weeks; all 15 were alive and healthy at 8 weeks. Thus, the doses of busulfan and cyclophosphamide we used were nonmyeloablative.
Donor hematopoietic chimerism was induced in lymphohematopoietic tissues
To evaluate donor chimerism in additional lymphohematopoietic tissue, we killed recipient mice at 20 weeks post transplant and measured donor chimerism in blood, spleen, thymus, and bone marrow. As shown at Figure 4 , high levels of donor-derived cells were found in peripheral blood, spleen and bone marrow. A low level of chimerism was detected in the thymus. The level of donor chimerism was significantly higher in the group with DST than the group without DST in all tested lymphohematopoietic tissues. The level of donor chimerism in peripheral blood and spleen was significantly higher in mice that received the rapamycin alone, anti-CD154 mAb and CTLA4Ig combined, or rapamycin and anti-CD154 mAb combined, as compared with those that received anti-CD154 mAb alone or CTLA4Ig alone (P Ͻ 0.05). Interestingly, in bone marrow, we noted no significant difference of donor chimerism in mice that received rapamycin alone, anti-CD154 mAb and CTLA4Ig combined, or rapamycin and anti-CD154 mAb combined or anti-CD154 mAb alone. However, donor chimerism in all of these groups was significantly higher than in the group that received CTLA4Ig alone (P Ͻ 0.05).
In the spleen, most donor-derived cells were B cells. We detected a range of 25.1% to 55.0% donor CD45R/B220 + B cells in chimeric mice at 20 weeks post transplant (Table  2) . A high level of donor CD3 + T cells was also detected in spleen of chimeric mice. The majority of T cells were CD4
+ . The level of donor CD3, CD4, and CD8-positive T cells and CD45R/B220-positive B cells in mice that received rapamycin alone, anti-CD154 mAb and CTLA4Ig combined, or rapamycin and anti-CD154 mAb, combined, was significantly higher than in the group that received anti-CD154 mAb alone or CTLA4Ig alone.
Donor-reactive T cells (V␤5
+ and V␤11 + ) were deleted in chimeric mice
V␤5.1/2
+ and V␤11 + TCR bearing T lymphocytes are clonally eliminated in mice expressing MHC-class II I-E and superantigen encoded by the mammary tumor virus-9 endogenous provirus. 12, 13 Since the donor Balb/c mouse strain expresses I-E and superantigen encoded by mammary tumor virus-9, developing thymocytes whose TCR contained V␤5.1/2 and V␤11 that bind to superantigen are deleted. However, these V␤ + T cells are not deleted in C57BL/6 recipient mice because they do not express I-E, although C57BL/6 mice expressing superantigen encoded by the mammary tumor virus-9 endogenous provirus, activation of V␤5.1/2 and V␤11 TCR bearing T cells by mammary tumor virus-9 is dependent on presentation of I-E. Reconstitution of Balb/c hematopoietic system in C57BL/6 mice caused activation and subsequent deletion of V␤5.1/2 and V␤11 TCR expressing T cells. This method has been used for measure-specific deletion of donor-reactive T cells after establishing mixed chimerism. 14, 15 Since V␤8 TCR expressing T cells were normal in both mouse strains we used, they were controls in our experiment. Totals of 22 chimeric mice and 12 nonchimeric mice were tested for V␤5.1/2, V␤8 and V␤11 expressing CD4 + T cells in the peripheral blood at 20 weeks post transplant. As shown in Figure 5 , the percentage of V␤8 expressing CD4 + T cells was not reduced in chimeric mice, compared with nonchimeric mice, or in naive Balb/c and C57BL/6 mice. However, V␤5.1/2 and V␤11-positive CD4 + T cells were significantly deleted in chimeric mice compared with naive C57BL/6 mice and nonchimeric mice (P Ͻ 0. 
In vitro donor-specific unresponsiveness was induced in chimeric mice
At 20 weeks post transplant, spleen cells from chimeric and nonchimeric C57BL/6 mice were used to perform MLR. We assessed proliferation by splenocytes from these mice against donor-specific and third-party stimulators. As shown in Figure 6 , proliferation of splenocytes from chim- eric C57BL/6 mice against donor Balb/c stimulators was markedly reduced, compared to proliferation by splenocytes from nonchimeric C57BL/6 mice and naive C57BL/6 mice. However, the response of chimeric mice to thirdparty C3H/He was not significantly different from the response of naive C57BL/6 mice and nonchimeric C57BL/6 mice.
IFN-␥ has been strongly linked to allograft rejection. To evaluate donor-specific reactive lymphocytes in our recipient mice, we determined the number of interferon-␥ secreting T cells in spleen cells from chimeric and nonchimeric mice by using the ELISPOT assay which is capable of detecting cytokines produced by single cells. As shown in Figure 7 , only a few IFN-␥ secreting cells were detected in either chimeric C57BL/6 mice or nonchimeric C57BL/6 mice when the spleen cells from the same strain (C57BL/6 mouse) were used as stimulators. The number of IFN-␥ secreting cells was significantly increased in the spleen cells of nonchimeric C57BL/6 mice under the stimulation of Balb/c mouse spleen cells. In contrast, the level of IFN-␥ secreting cells in the chimeric C57BL/6 mice was not increased above the background level. The number of IFN-␥ secreting cells in both chimeric C57BL/6 mice and nonchimeric C57BL/6 mice was slightly increased when third-party (C3H/He) spleen cells were used as the stimulators.
Discussion
Our study showed that, for engraftment of a modest dose of bone marrow, conditioning therapy is required to suppress the host's lymphohematopoietic system although complete destruction is not necessary. Hematopoietic macrochimerism could be induced across fully MHC-mismatched barriers under our nonirradiative and nonmyeloablative conditioning therapy with different posttransplant treatments. Hale et al 7 reported that 8-10% of donor chimerism and donor-specific tolerance could be induced after transplantation of megadoses of bone marrow combined with high doses of ALS and rapamycin. In our protocol, a relatively low dose of ALS was given because we found that the 0.5 ml ALS used by Hale et al was very toxic and associated with high mortality (data not shown). However, a low dose of ALS combined with rapamycin and costimulatory blockade did not induce any donor chimerism when a modest dose of bone marrow was infused. When busulfan and cyclophosphamide were added, a stable and high level of donor chimerism was achieved in all recipient mice. Thus, this conditioning therapy is very important. We also found that ALS is essential in this protocol since only one of six recipient mice that did not received ALS achieved donor hematopoietic chimerism.
As donor antigen pretreatment, DST has been widely used to induce donor-specific tolerance in different transplant models. It enhanced the induction of donor chimerism in our protocol. It stimulated and activated the allospecific reactive lymphocytes which were eliminated by ALS and cyclophosphamide. Cyclophosphamide, an alkylating agent, is immunosuppressive and is not myeloablative. Spleen cell or bone marrow pretreatment of the host followed by cyclophosphamide administration induces microchimerism and donor-specific tolerance in most H-2-matched combinations, 16, 17 but not in fully H-2-mismatched combinations. 9, 18 Tomita et al 18 showed that cyclophosphamide and busulfan as conditioning therapy did not result in bone marrow engraftment. However, macrochimerism could be induced when donor spleen cell treatment was given. It seems that myelosuppression is critical for donor marrow reconstitution. Adams et al 19 showed that titratable donor hematopoietic chimerism can be induced by infusion of two doses of T cell-depleted bone marrow and treatment with busulfan and costimulatory blockade. We did not explore the effect of busulfan alone in our protocol. Further study is needed to investigate its role in our protocol; it will be interesting to see if it can induce hematopoietic macrochimerism in our protocol.
Our results showed that rapamycin and costimulatory blockade as post-transplant treatment promote bone marrow engraftment and rapamycin is as effective as costimulatory blockade. Our dose of rapamycin is low compared with Hale et al's study. 7 In their study, rapamycin at a dose of 24 mg/kg was used to facilitate the establishment of mixed hematopoietic chimerism. Rapamycin blocks signal transduction and inhibits cell cycle progression. 20 However, it has a primary effect on lymphokine responses rather than lymphokine production. It has been shown that rapamycin prevents GVHD in mouse models. [21] [22] [23] In contrast to the calcineurin inhibitor, rapamycin does not block antigen priming for activation-induced cell death. 24, 25 Tolerance to allogeneic heart and skin grafts requires deletion of alloreactive T cells through activation-induced cell death. 26, 27 Li et al showed that rapamycin is compatible with costimulation blockade in tolerance induction for this reason. 26, 28 Our data also showed that rapamycin did not inhibit the effect of costimulatory blockade on promoting induction of hematopoietic macrochimerism.
Wekerle et al 5 showed that blocking CD28/B7s and CD40/CD154 pathways induced a level of about 15% donor chimerism when megadoses of bone marrow were infused. We found that blocking both CD28/B7s and CD40/CD154 pathways significantly enhanced the induction of donor chimerism in our protocol, as compared with either CD28/B7 alone or CD40/CD154 alone. Recently studies by Quesenberry et al 29 and Taylor et al 30 also showed that anti-CD154 mAb treatment promoted allogeneic bone marrow engraftment under low-dose irradiation as conditioning therapy. However, rapamycin has the actual advantage of promoting bone marrow engraftment in clinical application currently, compared with anti-CD154 mAb and CTLA4Ig, since rapamycin is a FDA approved drug. Conversion of mixed chimerism to full chimerism can be achieved by delaying lymphocyte infusion. 31 Using T cell-depleted bone marrow, Adams et al 19 showed that donor chimerism gradually increased after bone marrow transplantation. In our experiment, the level of donor chimerism gradually increased without any further manipulation after unmodified bone marrow infusion. For example, the level of donor chimerism in our DST-treated group rose from 55.7 Ϯ 18.6% at 2 weeks to 89.0 Ϯ 3.5%
Bone Marrow Transplantation at 20 weeks. Whether mixed chimerism can convert to full chimerism is unknown in our groups since we only monitored until 20 weeks post transplant.
Intrathymic clonal deletion is the main mechanism for inducing and maintaining tolerance. 32 Our results were consistent with these studies. We showed that populations of donor-reactive T cells were deleted in chimeric mice. Intrathymic clonal deletion leads to the absence of donorreactive cells and donor-specific tolerance. Although we did not investigate whether donor-specific tolerance was induced in our chimeric mice in vivo, we did study whether in vitro donor-specific tolerance was induced at 20 weeks post transplantation. Compared with the proliferation of splenocytes from nonchimeric mice, our MLR results demonstrated a remarkably reduced proliferation of splenocytes from chimeric mice against donor-specific stimulators. Donor-specific cytokine secreting cells were not found in chimeric mice as measured by our ELISPOT assay. We detected few donor-specific IFN-␥ secreting splenocytes in chimeric mice. However, we found high frequencies of donor-specific IFN-␥ secreting splenocytes in nonchimeric mice. These data clearly indicated that donor-specific tolerance was induced in these chimeric mice.
In summary, a stable and high level of hematopoietic donor chimerism could be induced across a fully MHCmismatched barrier under nonirradiative and nonmyeloablative therapy, without any evidence of GVHD. DST enhanced induction of donor chimerism in our protocol. Rapamycin and costimulatory blockade as post-transplant treatment promoted bone marrow engraftment.
